Immunogen, Inc.

Acceleron Pharma Inc.

The Brigham and Women's Hospital, Inc.

Janssen Biotech, Inc.

Accleron Pharma Inc.

Rita M Steeves

Ravindra Kumar

Ravi V J Chari

Asya Grinberg

Dianne S Sako

Roselyne Castonguay

Walter A Blattler

Robert J Lutz

Viktor S Goldmakher

Yelena V Kovtun

John M Lambert

Paul B Yu

Hans K Erickson

Wayne Charles Widdison

Godfrey W Amphlett

Walter Anton Blättler

Qiming Chen

Godfrey Amphlett

In some aspects, the invention teaches pharmaceutical compositions that include a TGF-β ligand trap, and methods of using a TGF-β ligand trap to treat, prevent, or reduce the progression rate of pulmonary hypertension (PH). The invention also provides methods of using a TGF-β ligand trap to treat, prevent, or reduce the progression rate of a variety of conditions including, but not limited to, pulmonary vascular remodeling, pulmonary fibrosis, right ventricular hypertrophy, diseases associated with excessive TGF-β signaling, diseases associated with excessive GDF15 signaling, and diseases associated with excessive PAI-1 signaling. The invention further provides methods of using a TGF-β ligand trap to reduce right ventricular systolic pressure in a subject.

Methods for treating pulmonary hypertension with a ligand binding domain of a TGF-beta type II receptor

In certain aspects, the present disclosure relates to polypeptides comprising a truncated, ligand-binding portion of the extracellular domain of T&#x3b2;RII polypeptide useful to selectively antagonize a T&#x3b2;RII ligand. The disclosure further provides compositions and methods for use in treating or preventing TGF&#x3b2; associated disorders.

Methods of treating a fibrotic disorder by administering transforming growth factor beta receptor II fusion polypeptides

Methods of treating a sclerotic disorder by administering a transforming growth factor beta receptor type II fusion polypeptide

In some aspects, the invention teaches pharmaceutical compositions that include a TGF-beta ligand trap, and methods of using a TGF-beta ligand trap to treat, prevent, or reduce the progression rate of pulmonary hypertension (PH). The invention also provides methods of using a TGF-beta ligand trap to treat, prevent, or reduce the progression rate of a variety of conditions including, but not limited to, pulmonary vascular remodeling, pulmonary fibrosis, right ventricular hypertrophy, diseases associated with excessive TGF-beta signaling, diseases associated with excessive GDF15 signaling, and diseases associated with excessive PAI-1 signaling. The invention further provides methods of using a TGF-beta ligand trap to reduce right ventricular systolic pressure in a subject.

Methods for treating pulmonary hypertension with a TGF-beta type II receptor-FC fusion protein

Transforming growth factor-beta receptor type II fusion polypeptides

Transforming growth factor beta receptor II fusion polypeptides

The invention relates to conjugates of anti-integrin specific antibodies with cytotoxic compounds, the synthesis, selection, and use of such conjugates for use in cancer therapy or other diseases mediated by cell proliferation, cell migration, or inflammation and which pathology involves angiogenesis or neovascularization of new tissue. In addition the invention relates to combination therapy of such diseases wherein the treatment comprises use of said conjugates in combination with one or more other treatment modalities including but not limited to: chemotherapy, surgery or radiation therapy. The preferred conjugates contain maytansinoid compounds linked to the antibody by a disulfide linkage, and preferred chemotherapeutic agents are doxorubicin, a taxane, a camptothecin, a podophyllotoxin, a nucleoside analog, or a pyrimidine analog.

Anti-integrin immunoconjugates, methods and uses

Methods of killing or inhibiting tumors comprising of heterogeneous or mixed cell populations is described. The killing or inhibition of tumors is achieved by selectively targeting a unique ligand suspected of being expressed on a particular cell population to also kill a cell population lacking the unique ligand. These conjugates have therapeutic use as they are delivered to a specific cell population to kill these cells and the cytotoxic drug is released to kill non-targeted cells, thereby eliminating the tumor.

Elimination of heterogeneous or mixed cell population in tumors

The present invention discloses a method for targeting maytansinoids to a selected cell population, the method comprising contacting a cell population or tissue suspected of containing the selected cell population with a cell-binding agent maytansinoid conjugate, wherein one or more maytansinoids is covalently linked to the cell-binding agent via a non-cleavable linker and the cell-binding agent binds to cells of the selected cell population.

Method of targeting specific cell populations using cell-binding agent maytansinoid conjugates linked via a non-cleavable linker, said conjugates and methods of making said conjugates

Method of targeting specific cell populations using cell-binding agent maytansinoid conjugates linked via a non-cleavable linker, said conjugates, and methods of making said conjugates

Growing community of inventors

StoneHame, MA, United States of America

Rita M Steeves